Senators Scrutinize Mylan Over EpiPen’s U.S. Price Increases

  • Grassley asks drugmaker to provide information on pricing
  • Klobuchar calls for FTC to look into business practices

Two senior U.S. senators are examining Mylan NV’s price increases for the popular EpiPen allergy shot, with lawmakers saying the drugmaker’s practices may have limited competition and access to the treatment.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.